Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA.

Cell Death Dis. 2018 Jul 24;9(8):810. doi: 10.1038/s41419-018-0865-6.

2.

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.

Muralidharan SV, Einarsdottir BO, Bhadury J, Lindberg MF, Wu J, Campeau E, Bagge RO, Stierner U, Ny L, Nilsson LM, Nilsson JA.

Cell Death Dis. 2017 Aug 10;8(8):e2982. doi: 10.1038/cddis.2017.383. Erratum in: Cell Death Dis. 2017 Dec 14;8(12 ):e3177.

3.

BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.

Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):E5930-E5939. doi: 10.1073/pnas.1705206114. Epub 2017 Jul 6.

4.

Corrigendum: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.

Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T, Einarsdottir BO, Saleh A, Göktürk C, Baranczewski P, Svensson R, Berntsson RP, Gustafsson R, Strömberg K, Sanjiv K, Jacques-Cordonnier MC, Desroses M, Gustavsson AL, Olofsson R, Johansson F, Homan EJ, Loseva O, Bräutigam L, Johansson L, Höglund A, Hagenkort A, Pham T, Altun M, Gaugaz FZ, Vikingsson S, Evers B, Henriksson M, Vallin KSA, Wallner OA, Hammarström LGJ, Wiita E, Almlöf I, Kalderén C, Axelsson H, Djureinovic T, Carreras Puigvert J, Häggblad M, Jeppsson F, Martens U, Lundin C, Lundgren B, Granelli I, Jenmalm Jensen A, Artursson P, Nilsson JA, Stenmark P, Scobie M; Ulrika Warpman Berglund &Thomas Helleday.

Nature. 2017 Apr 26;544(7651):508. doi: 10.1038/nature22083. No abstract available.

PMID:
28447629
5.

Validation and development of MTH1 inhibitors for treatment of cancer.

Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, Chernobrovkin A, Manoilov A, Pateras IS, Rasti A, Jemth AS, Almlöf I, Loseva O, Visnes T, Einarsdottir BO, Gaugaz FZ, Saleh A, Platzack B, Wallner OA, Vallin KS, Henriksson M, Wakchaure P, Borhade S, Herr P, Kallberg Y, Baranczewski P, Homan EJ, Wiita E, Nagpal V, Meijer T, Schipper N, Rudd SG, Bräutigam L, Lindqvist A, Filppula A, Lee TC, Artursson P, Nilsson JA, Gorgoulis VG, Lehtiö J, Zubarev RA, Scobie M, Helleday T.

Ann Oncol. 2016 Dec;27(12):2275-2283. doi: 10.1093/annonc/mdw429. Epub 2016 Nov 8.

6.

Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.

Bhadury J, Einarsdottir BO, Podraza A, Bagge RO, Stierner U, Ny L, Dávila López M, Nilsson JA.

Oncotarget. 2016 Apr 26;7(17):23801-11. doi: 10.18632/oncotarget.8181.

7.

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions.

Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truvé K, López MD, Naredi P, Nilsson O, Stierner U, Ny L, Nilsson JA.

Oncotarget. 2014 Oct 30;5(20):9609-18.

8.

MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.

Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T, Einarsdottir BO, Saleh A, Göktürk C, Baranczewski P, Svensson R, Berntsson RP, Gustafsson R, Strömberg K, Sanjiv K, Jacques-Cordonnier MC, Desroses M, Gustavsson AL, Olofsson R, Johansson F, Homan EJ, Loseva O, Bräutigam L, Johansson L, Höglund A, Hagenkort A, Pham T, Altun M, Gaugaz FZ, Vikingsson S, Evers B, Henriksson M, Vallin KS, Wallner OA, Hammarström LG, Wiita E, Almlöf I, Kalderén C, Axelsson H, Djureinovic T, Puigvert JC, Häggblad M, Jeppsson F, Martens U, Lundin C, Lundgren B, Granelli I, Jensen AJ, Artursson P, Nilsson JA, Stenmark P, Scobie M, Berglund UW, Helleday T.

Nature. 2014 Apr 10;508(7495):215-21. doi: 10.1038/nature13181. Epub 2014 Apr 2. Erratum in: Nature. 2017 Apr 26;544(7651):508.

PMID:
24695224
9.

Hip fractures and bone mineral density in the elderly--importance of serum 25-hydroxyvitamin D.

Steingrimsdottir L, Halldorsson TI, Siggeirsdottir K, Cotch MF, Einarsdottir BO, Eiriksdottir G, Sigurdsson S, Launer LJ, Harris TB, Gudnason V, Sigurdsson G.

PLoS One. 2014 Mar 12;9(3):e91122. doi: 10.1371/journal.pone.0091122. eCollection 2014.

10.

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer.

Reynisdottir I, Arason A, Einarsdottir BO, Gunnarsson H, Staaf J, Vallon-Christersson J, Jonsson G, Ringnér M, Agnarsson BA, Olafsdottir K, Fagerholm R, Einarsdottir T, Johannesdottir G, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB.

Cancer Med. 2013 Aug;2(4):437-46. doi: 10.1002/cam4.88. Epub 2013 May 22.

11.

Prevention of congenital rubella in Iceland by antibody screening and immunization of seronegative females.

Gudmundsdóttir S, Antonsdóttir A, Gudnadóttir S, Elefsen S, Einarsdóttir B, Olafsson O, Gudnadóttir M.

Bull World Health Organ. 1985;63(1):83-92.

12.
13.

Direct HIG test for rubella antibodies.

Einarsdóttir B, Rafnar B.

J Med Virol. 1980;5(4):303-8.

PMID:
7014781

Supplemental Content

Loading ...
Support Center